8-K current report · filed Oct 22, 2026

Aardvark Therapeutics, Inc. (AARD) 8-K Current Report: October 22, 2026

Item 8.01Item EX-99.1AARD overview

Short answer

Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA lifted the clinical hold on ARD-101’s Investigational New Drug application.

Aardvark Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA lifted the clinical hold on ARD-101’s Investigational New Drug application
  • Regulatory clearance enables clinical development for hyperphagia in Prader-Willi Syndrome
  • Investor conference call scheduled for October 23, 2026 at 8:00 a.m. ET
  • Exhibit 99.1 contains the company’s full announcement

Item EX-99.1 · Exhibit EX-99.1

  • FDA lifted the clinical hold on ARD-101, reopening a path for Prader-Willi Syndrome development
  • Prior hold followed reversible ECG changes, creating a key cardiac-safety overhang for investors
  • No cardiac events observed at 200 mg and 400 mg twice-daily doses in the additional ECG study
  • Phase 3 resumption still depends on FDA alignment regarding trial design, with possible additional studies
  • October 23 webcast will review unblinded HERO and OLE data, though both trials terminated early and were not efficacy-powered

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aardvark Therapeutics, Inc. 8-K filings

Get the next AARD 8-K as it lands

Follow AARD for push alerts, or ask the research agent what this filing means.